Clinical genetic testing for patients with autism spectrum disorders - PubMed (original) (raw)
Comparative Study
. 2010 Apr;125(4):e727-35.
doi: 10.1542/peds.2009-1684. Epub 2010 Mar 15.
Kira A Dies, Ingrid A Holm, Carolyn Bridgemohan, Magdi M Sobeih, Elizabeth B Caronna, Karen J Miller, Jean A Frazier, Iris Silverstein, Jonathan Picker, Laura Weissman, Peter Raffalli, Shafali Jeste, Laurie A Demmer, Heather K Peters, Stephanie J Brewster, Sara J Kowalczyk, Beth Rosen-Sheidley, Caroline McGowan, Andrew W Duda 3rd, Sharyn A Lincoln, Kathryn R Lowe, Alison Schonwald, Michael Robbins, Fuki Hisama, Robert Wolff, Ronald Becker, Ramzi Nasir, David K Urion, Jeff M Milunsky, Leonard Rappaport, James F Gusella, Christopher A Walsh, Bai-Lin Wu, David T Miller; Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration
Collaborators, Affiliations
- PMID: 20231187
- PMCID: PMC4247857
- DOI: 10.1542/peds.2009-1684
Comparative Study
Clinical genetic testing for patients with autism spectrum disorders
Yiping Shen et al. Pediatrics. 2010 Apr.
Abstract
Background: Multiple lines of evidence indicate a strong genetic contribution to autism spectrum disorders (ASDs). Current guidelines for clinical genetic testing recommend a G-banded karyotype to detect chromosomal abnormalities and fragile X DNA testing, but guidelines for chromosomal microarray analysis have not been established.
Patients and methods: A cohort of 933 patients received clinical genetic testing for a diagnosis of ASD between January 2006 and December 2008. Clinical genetic testing included G-banded karyotype, fragile X testing, and chromosomal microarray (CMA) to test for submicroscopic genomic deletions and duplications. Diagnostic yield of clinically significant genetic changes was compared.
Results: Karyotype yielded abnormal results in 19 of 852 patients (2.23% [95% confidence interval (CI): 1.73%-2.73%]), fragile X testing was abnormal in 4 of 861 (0.46% [95% CI: 0.36%-0.56%]), and CMA identified deletions or duplications in 154 of 848 patients (18.2% [95% CI: 14.76%-21.64%]). CMA results for 59 of 848 patients (7.0% [95% CI: 5.5%-8.5%]) were considered abnormal, which includes variants associated with known genomic disorders or variants of possible significance. CMA results were normal in 10 of 852 patients (1.2%) with abnormal karyotype due to balanced rearrangements or unidentified marker chromosome. CMA with whole-genome coverage and CMA with targeted genomic regions detected clinically relevant copy-number changes in 7.3% (51 of 697) and 5.3% (8 of 151) of patients, respectively, both higher than karyotype. With the exception of recurrent deletion and duplication of chromosome 16p11.2 and 15q13.2q13.3, most copy-number changes were unique or identified in only a small subset of patients.
Conclusions: CMA had the highest detection rate among clinically available genetic tests for patients with ASD. Interpretation of microarray data is complicated by the presence of both novel and recurrent copy-number variants of unknown significance. Despite these limitations, CMA should be considered as part of the initial diagnostic evaluation of patients with ASD.
Similar articles
- Confirmation of chromosomal microarray as a first-tier clinical diagnostic test for individuals with developmental delay, intellectual disability, autism spectrum disorders and dysmorphic features.
Battaglia A, Doccini V, Bernardini L, Novelli A, Loddo S, Capalbo A, Filippi T, Carey JC. Battaglia A, et al. Eur J Paediatr Neurol. 2013 Nov;17(6):589-99. doi: 10.1016/j.ejpn.2013.04.010. Epub 2013 May 24. Eur J Paediatr Neurol. 2013. PMID: 23711909 - Diagnostic yield of chromosomal microarray analysis in an autism primary care practice: which guidelines to implement?
McGrew SG, Peters BR, Crittendon JA, Veenstra-Vanderweele J. McGrew SG, et al. J Autism Dev Disord. 2012 Aug;42(8):1582-91. doi: 10.1007/s10803-011-1398-3. J Autism Dev Disord. 2012. PMID: 22089167 - Chromosomal microarray testing influences medical management.
Coulter ME, Miller DT, Harris DJ, Hawley P, Picker J, Roberts AE, Sobeih MM, Irons M. Coulter ME, et al. Genet Med. 2011 Sep;13(9):770-6. doi: 10.1097/GIM.0b013e31821dd54a. Genet Med. 2011. PMID: 21716121 - Diagnostic yield of genetic testing in children diagnosed with autism spectrum disorders at a regional referral center.
Roesser J. Roesser J. Clin Pediatr (Phila). 2011 Sep;50(9):834-43. doi: 10.1177/0009922811406261. Epub 2011 Apr 27. Clin Pediatr (Phila). 2011. PMID: 21525079 Review. - Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.
Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, Church DM, Crolla JA, Eichler EE, Epstein CJ, Faucett WA, Feuk L, Friedman JM, Hamosh A, Jackson L, Kaminsky EB, Kok K, Krantz ID, Kuhn RM, Lee C, Ostell JM, Rosenberg C, Scherer SW, Spinner NB, Stavropoulos DJ, Tepperberg JH, Thorland EC, Vermeesch JR, Waggoner DJ, Watson MS, Martin CL, Ledbetter DH. Miller DT, et al. Am J Hum Genet. 2010 May 14;86(5):749-64. doi: 10.1016/j.ajhg.2010.04.006. Am J Hum Genet. 2010. PMID: 20466091 Free PMC article. Review.
Cited by
- Sexually dimorphic phenotypes and the role of androgen receptors in UBE3A-dependent autism spectrum disorder.
Tian Y, Qiao H, Zhu LQ, Man HY. Tian Y, et al. bioRxiv [Preprint]. 2024 May 4:2024.05.02.592248. doi: 10.1101/2024.05.02.592248. bioRxiv. 2024. PMID: 38746146 Free PMC article. Preprint. - Exploring genetic testing requests, genetic alterations and clinical associations in a cohort of children with autism spectrum disorder.
Garrido-Torres N, Marqués Rodríguez R, Alemany-Navarro M, Sánchez-García J, García-Cerro S, Ayuso MI, González-Meneses A, Martinez-Mir A, Ruiz-Veguilla M, Crespo-Facorro B. Garrido-Torres N, et al. Eur Child Adolesc Psychiatry. 2024 Apr 8. doi: 10.1007/s00787-024-02413-x. Online ahead of print. Eur Child Adolesc Psychiatry. 2024. PMID: 38587680 - Evaluation of DNA repair capacity in parents of pediatric patients diagnosed with autism spectrum disorder using the comet assay procedure.
Akouchekian M, Alizadeh R, Beiranvandi F, Dehghan Manshadi M, Taherizadeh F, Hakim Shooshtari M. Akouchekian M, et al. IBRO Neurosci Rep. 2023 Oct 19;15:304-309. doi: 10.1016/j.ibneur.2023.10.003. eCollection 2023 Dec. IBRO Neurosci Rep. 2023. PMID: 37885831 Free PMC article. - Knowledge, attitudes and experiences of genetic testing for autism spectrum disorders among caregivers, patients, and health providers: A systematic review.
Zhou M, Zhang YM, Li T. Zhou M, et al. World J Psychiatry. 2023 May 19;13(5):247-261. doi: 10.5498/wjp.v13.i5.247. eCollection 2023 May 19. World J Psychiatry. 2023. PMID: 37303934 Free PMC article. - Diagnostic yield and clinical impact of chromosomal microarray analysis in autism spectrum disorder.
Cucinotta F, Lintas C, Tomaiuolo P, Baccarin M, Picinelli C, Castronovo P, Sacco R, Piras IS, Turriziani L, Ricciardello A, Scattoni ML, Persico AM. Cucinotta F, et al. Mol Genet Genomic Med. 2023 Aug;11(8):e2182. doi: 10.1002/mgg3.2182. Epub 2023 Apr 25. Mol Genet Genomic Med. 2023. PMID: 37186221 Free PMC article.
References
- Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry. 2005;66(suppl 10):3–8. - PubMed
- Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol Psychiatry. 2007;12(1):2–22. - PubMed
- Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genet Med. 2008;10(1):4–12. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical